Methotrexate Orion

Methotrexate, the active ingredient in Methotrexate Orion, is an antimetabolite (folate antagonist) presented as an oral formulation for oral use. It is employed to modify disease activity in rheumatoid arthritis, manage severe psoriasis, and treat certain cancers such as acute lymphoblastic leukemia and non‑Hodgkin lymphoma.

GNH USA supplies Methotrexate Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, ensuring consistent quality and regulatory compliance. The company adheres to EU GMP standards and provides reliable logistics for global distribution.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: limits skin cell proliferation and improves plaque severity. - Acute lymphoblastic leukemia: interferes with leukemic cell replication to achieve remission. - Non‑Hodgkin lymphoma: hampers malignant lymphocyte growth. - Gestational trophoblastic disease: induces regression of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mouth sores or ulceration. - Mild liver enzyme elevation. - Low white blood cell count. - Hair thinning or loss.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Significant bone marrow suppression leading to anemia. - Renal impairment or failure. - Life‑threatening infections due to immunosuppression. - Rare cutaneous reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, several safety considerations should be observed.

- Pregnancy: contraindicated (Category X); avoid use in pregnant or planning patients. - Liver function: monitor enzymes regularly; adjust if significant elevation occurs. - Renal function: assess creatinine clearance; dose may need modification. - Hematology: perform complete blood counts to detect marrow suppression. - Concomitant folate: supplement with folic acid to reduce mucosal toxicity. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and direct sunlight.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors: may raise methotrexate serum levels. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): potentiate bone marrow suppression.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin): may reduce methotrexate effectiveness. - Vitamin supplements containing folic acid: can diminish therapeutic impact. - Live vaccines: increased infection risk; avoid during treatment.